BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.17.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250731T120000
DTEND;TZID=America/Los_Angeles:20250731T130000
DTSTAMP:20250513T235311Z
CREATED:20250512T144339Z
LAST-MODIFIED:20250513T235311Z
UID:41960-1753963200-1753966800@solvecfs.org
SUMMARY:Probing Functional Autoantibodies in Patients with ME/CFS
DESCRIPTION:Dr. Akiko Iwasaki (Sterling Professor of Immunobiology and Molecular\, Cellular and Developmental Biology at Yale University) is the first recipient of Solve’s ME/CFS Catalyst Award in support of her study\, “Probing Functional Autoantibodies in Patients with ME/CFS.” \nIn this webinar\, Dr. Iwasaki will talk to Solve CEO Emily Taylor about the study\, which focuses on a crucial and emerging area of investigation: the role of autoantibodies—antibodies that mistakenly target a person’s own tissues—in the long-term neurological symptoms seen in patients with ME/CFS. \nDr. Iwasaki’s lab will investigate whether these autoantibodies can actually cause symptoms such as fatigue\, pain\, cognitive issues\, and motor dysfunction by introducing patient-derived antibodies into mice and analyzing their effects. The team will also use an advanced technology (called HuProt) to scan all human proteins to find which ones are targeted by specific autoantibodies. Autoantibodies against specific human proteins may be effective biomarkers—measurable features that help us diagnose patients quicker or customize how we treat each patient. \nThe study is remarkable because it: \n• Links Autoimmunity to ME/CFS: Helps determine whether immune system dysfunction is a root cause of neurological [SB3] symptoms in ME/CFS. \n• Lays the Groundwork for Targeted Treatments: Could identify which patients benefit most from existing immune-based therapies (like B-cell depletion or antibody-blocking drugs). \n• Advances Diagnostic Tools: Could find biomarkers that lead to the development of long-overdue diagnostic tests. \n• Bridges the Gap Between Long COVID and ME/CFS: Builds on recent research in long COVID\, creating momentum for both communities. \n• Centers Patient Experience: Is directly informed by the real-life neurological symptoms and struggles of people living with ME/CFS. \n  \nAfter her presentation and as time allows\, Dr. Iwasaki will take questions from the audience. \nRegister here: \nhttps://us02web.zoom.us/webinar/register/WN_byWyT5GoQfyLwYP3t0qruw
URL:https://solvecfs.org/event/probing-functional-autoantibodies-in-patients-with-me-cfs/
CATEGORIES:Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/05/IwasakiSolveWebinarV412pmPT.png
END:VEVENT
END:VCALENDAR